Regenerx Biopharmaceuticals Inc (RGRX) 0.5000 $RGRX
Global Traumatic Brain Injury Pipeline Report 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9f9f48/traumatic_brain) has announced the addition of the "Traumatic Brain Injury - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Traumatic Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adamas Pharmaceuticals, Inc. - ALSP, Inc. - Amarantus Bioscience Holdings, Inc. - Athersys, Inc. - BHR Pharma, LLC - Cognosci, Inc. - Concert Pharmaceuticals, Inc. - Euroscreen S.A. - Grupo Ferrer Internacional, S.A. - International Stem Cell Corporation - Io Therapeutics, Inc. - Ischemix - Karyopharm Therapeutics, Inc. - Kyorin Pharmaceutical Co., Ltd. - Levolta Pharmaceuticals, Inc. - Lixte Biotechnology Holdings, Inc. - Lpath, Inc. - MandalMed, Inc. - Mapreg S.A.S. - Mnemosyne Pharmaceuticals, Inc. - NeoStem, Inc. - Neuralstem, Inc. - Neuren Pharmaceuticals Limited - PharmatrophiX, Inc. - Phylogica Limited - Prevacus, Inc. - PsychoGenics, Inc. - QR Pharma, Inc. - RAPID Pharmaceuticals AG - RegeneRx Biopharmaceuticals, Inc. - SynZyme Technologies, LLC - Tetra Discovery Partners LLC - vasopharm GmbH - VG Life Sciences, Inc. For more information visit http://www.researchandmarkets.com/research/9f...atic_brain
NBS: 2.37 (-0.01), LPTN: 1.75 (-0.08), CNCE: 14.20 (+0.07), ATHX: 1.33 (+0.06), KPTI: 27.02 (+2.21), CUR: 1.71 (+0.01)
Researchers Report that Long-Term Administration of Thymosin B4 in a Diabetic Animal Model Prevents Progression of Peripheral Neuropathy and Restores Sciatic Nerve Function
PR Newswire - Fri May 08, 8:00AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that independent researchers have reported that diabetic mice treated long-term with Thymosin B4 (TB4) have significantly improved motor and sensory function in the sciatic nerve compared to the untreated animals and that TB4 protects the nerves and reverses neurological damage in diabetic neuropathy.
Penny Stocks Alerts for RegeneRx, Key Energy Services, Zynga, American Security Resources, Axxess Pharma, and Ecosciences
PR Newswire - Wed May 06, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: RegeneRx Biopharmaceuticals (OTCMKTS:RGRX), Key Energy Services (NYSE:KEG), Zynga (NASDAQ:ZNGA), American Security Resources (OTCMKTS:ARSC), Axxess Pharma (OTCMKTS:AXXE), and Ecosciences (OTCMKTS:ECEZ).
KEG: 2.55 (-0.05), ZNGA: 2.97 (-0.08)
Researchers Report that Thymosin B4 has a Major Role in Dermal Burn Wound Healing
PR Newswire - Mon May 04, 7:32AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"
today announced that an independent team of researchers from South Korea have reported that Thymosin B4 (TB4) plays an important role in accelerating the repair of second-degree dermal burn wounds, induced in an experimental mouse model, by promoting blood vessel formation and causing rapid vascular remodeling of damaged dermal tissue. The research found that the underlying mechanism of action is via actin cytoskeletal remodeling and the action of heat-shock proteins, which are induced when tissues or cells are exposed to stress. Heat shock proteins function to allow other proteins to assume their correct structures. The research also confirmed that remodeling of F-actin was regulated by TB4 by demonstrating its healing effects in the in vivo model.
RegeneRx awarded US PTO's notice of allowance for TB4 for healing and reversing cardiac tissue
M2 - Fri Apr 24, 5:17AM CDT
RegeneRx Biopharmaceuticals (Other OTC:RGRX) reported on Thursday the receipt of a Notice of Allowance from the US Patent and Trademark Office (PTO) for its patent application claiming the administration of Thymosin beta 4 (TB4) to treat cardiac tissue.
RegeneRx Receives Notice of Allowance For U.S. Patent For Healing and Reversing Heart and Coronary Vessel Damage After A Heart Attack with TB4
PR Newswire - Thu Apr 23, 9:24AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx" today announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application claiming the administration of Thymosin beta 4 (TB4) to treat cardiac tissue to heal and reverse heart and coronary vessel damage due to a heart attack, as well as to enhance the transition of immature heart cells into mature cells, among others.
RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S.
PR Newswire - Thu Apr 16, 8:53AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx" today announced its U.S. joint venture with G-treeBNT (ReGenTree LLC) has retained Ora, Inc. to conduct a phase 3 clinical trial for the orphan disorder, neurotrophic keratopathy (NK), and a 2b/3 dose-response, confirmatory trial for dry eye syndrome (DES) in the U.S. Both trials will be testing ReGenTree's preservative-free eye drops, RGN-259/GBT201, this year. Each of these eye disorders was being targeted by RegeneRx prior to entering into the joint venture.
/C O R R E C T I O N -- RegeneRx Biopharmaceuticals, Inc./
PR Newswire - Wed Apr 01, 8:40AM CDT
In the news release, RegeneRx's RGN-259 Meets Key Efficacy Objectives in Phase 2 Clinical Trial in Patients with Severe Dry Eye Reported in Current Issue of Cornea, issued 01-Apr-2015 by RegeneRx Biopharmaceuticals, Inc. over PR Newswire, we are advised by the company that there were changes to the second paragraph of the release. The complete, corrected release follows:
RegeneRx's RGN-259 Meets Key Efficacy Objectives in Phase 2 Clinical Trial in Patients with Severe Dry Eye Reported in Current Issue of Cornea
PR Newswire - Wed Apr 01, 7:36AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx" today announced that a new medical paper has been published describing the positive effects of Thymosin beta 4 (TB4) in patients with severe dry eye. The results met key efficacy objectives of the study and the physicians stated that statistically significant differences in both signs and symptoms of severe dry eye were seen at various time points throughout the study. Of particular note at day 56, the RGN-259-treated group had 35.1% reduction of ocular discomfort compared with vehicle control (P=0.0141), and 59.1% reduction of total corneal fluorescein staining compared with vehicle control (P = 0.0108). Other improvements seen in the RGN-259-treated patients included tear film breakup time and increased tear volume production.
RegeneRx Receives Israeli Patent Acceptance Notice for the Use of TB4 To Prevent Tissue Damage Associated with Heart Attack and Stroke Treatments
PR Newswire - Thu Mar 26, 9:26AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX)("the Company" or "RegeneRx" today announced that it has received a patent acceptance notice from the Israeli patent office with claims for administering Thymosin beta 4 (TB4) to prevent or reduce tissue damage caused by an increase in blood flow, as is often the case when cardiac vessels are opened after a blockage causing a heart attack or in similar circumstances when treating stroke victims.
RegeneRx Receives Initial Payment for RGN-259 U.S. License to ReGenTree Joint Venture
PR Newswire - Wed Mar 25, 7:55AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or the "Company" has received an initial payment of $500,000 from ReGenTree, LLC, its U.S. joint venture with G-TreeBNT Co. Ltd., pursuant to a license of RGN-259 for ophthalmic indications to ReGenTree. RegeneRx expects to receive a second payment of $500,000 later this year upon enrollment of the first patient in a U.S. ophthalmic clinical trial sponsored by ReGenTree. ReGenTree is planning a Phase III trial for neurotrophic keratopathy (an orphan indication) and a Phase II trial for dry eye syndrome in the U.S., both to begin later this year.
RegeneRx Joint Venture Partner Receives $7.28 million USD From Korean Government and Venture Fund for U.S. Development of RGN-259/GBT-201
PR Newswire - Mon Mar 09, 7:30AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" has been notified that its joint venture partner and licensee, G-treeBNT Co. Ltd., will receive $7.28 million USD to expand international development of its product candidate, RGN-259 (designated GBT-201).
Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases
PR Newswire - Tue Mar 03, 8:00AM CST
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx" In an editorial in the scientific journal, Expert Opinion on Biological Therapy, Dr. Michael Chopp and his colleague, Dr. Zhenggang Zhang, at the Henry Ford Hospital in Detroit, Michigan reported that Thymosin beta 4 (TB4) has the capacity to promote CNS and peripheral nervous system (PNS) remodeling 24 hours or more post-injury, leading to neurological recovery in each case. They pointed out that oligodendrogenesis and myelination are two of several common links in their studies by which TB4 promotes "self-recovery" and suggest that treatment strategies should be focused on pharmacologically enhancing the brain's own restorative abilities.
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics Pipeline Review 2015 - 10 Drug Profiles & 16 Drug Profiles
M2 - Tue Mar 03, 6:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/mh4n22/peripheral) has announced the addition of the "Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acorda Therapeutics, Inc. - aTyr Pharma, Inc. - GeNeuro SA - INSYS Therapeutics, Inc. - Mitsubishi Tanabe Pharma Corporation - Neuren Pharmaceuticals Limited - Pfizer Inc. - RegeneRx Biopharmaceuticals, Inc. - Takeda Pharmaceutical Company Limited - Teijin Pharma Limited Drug Profiles - cannabidiol - fingolimod hydrochloride - GL-2045 - immune globulin (human) - Monoclonal Antibody for CIDP - NNZ-2591 - NP-1998 - NRP-2945 - Peptide to Activate GLP1R for CNS, Metabolic Disorders and Head Trauma - Peptides for Neuropathic Pain and Peripheral Neuropathy - Peptides to Activate GLP-1 Receptor for CNS Disorders and Head Trauma - Proteins for Inflammation, Hematological, Metabolic, Oncology, Neurodegenerative and Cardiovascular Disorder - RGN-352 - Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis - Small Molecules to Inhibit Cysteine Protease and Caspases for Oncology, Immunology, Infectious and CNS Disorders - Synthetic Peptides for Peripheral Neuropathy For more information visit http://www.researchandmarkets.com/research/mh4n22/peripheral
INSY: 59.68 (+0.68), PFE: 33.98 (-0.01), ACOR: 30.71 (+0.67)
RegeneRx Updates Website
PR Newswire - Thu Feb 19, 7:30AM CST
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx" updated its website to reflect recent commercial transactions and information related to development of its clinical products. The site can be accessed at www.regenerx.com.
RegeneRx Releases Letter to Shareholders
PR Newswire - Tue Feb 17, 7:30AM CST
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx" today released the following letter to shareholders:
Sensory Neuropathy Therapeutics Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com
PRWeb - Tue Feb 10, 7:31AM CST
The report "Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy). Peripheral Neuropathy (Sensory Neuropathy) is a damage to one or more of peripheral nerves that includes motor, sensory and autonomic fibers. The cause of peripheral neuropathy is often unidentified. The most widespread causes of peripheral neuropathy are diabetes, shingles, kidney failure, various drugs and vitamin shortage. When the peripheral sensory nerves are damaged, they fail to send sensory messages (pain, heat, touch, cold etc). Neuropathy occurs in 60% to 70% of people with diabetes. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available @ http://www.rnrmarketresearch.com/peripheral-n...eport.html .
PFE: 33.98 (-0.01)
RegeneRx & G-treeBNT partnership to develop RGN-259 in the US for ophthalmic indications
M2 - Fri Jan 30, 2:14AM CST
Biopharmaceutical company RegeneRx Biopharmaceuticals (Other OTC:RGRX) reported on Wednesday the launch of an agreement to develop RGN-259 for dry eye syndrome and neurotrophic keratitis (an orphan indication) in the US in partnership with Korean-based pharma company G-treeBNT Co.
RegeneRx and G-treeBNT Create Joint Venture to Develop RGN-259 in the U.S.
PR Newswire - Wed Jan 28, 11:11AM CST
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx" today announced that it has entered into agreements with G-treeBNT Co. Ltd., to develop RGN-259 for dry eye syndrome and neurotrophic keratitis (an orphan indication) in the United States. Under the terms of a joint venture (JV) agreement between the parties, G-treeBNT will be responsible for conducting and funding all clinical trials and product development through approval of a new drug application (NDA). Pursuant to the terms of a license agreement between RegeneRx and the joint venture entity, RegeneRx granted the JV an exclusive, royalty-bearing license to market and sell RGN-259 in the U.S. RegeneRx also contributed all of its non-clinical and clinical data generated to date. G-treeBNT will hold a majority equity stake in the JV that will increase as it successfully reaches development milestones. RegeneRx has the right to participate in all key development and commercialization decisions under the agreements, including the right to approve key commercial relationships and transactions, such as product licensing, mergers or acquisitions.
RegeneRx Partner Submits Phase IIB/III IND to Korean Health Authority for RGN-259 for the Treatment of Dry Eye Syndrome
PR Newswire - Mon Dec 29, 7:30AM CST
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" announced that its strategic partner, G-treeBNT Co. Ltd., has filed an IND with the Korean Ministry of Food and Drug Safety (MFDS) for a Phase IIB/III clinical trial with RGN-259 (designated GBT-201 in Korea and the licensed Pan Asia territory) for the treatment of patients with dry eye syndrome.
Global Traumatic Brain Injury Pipeline Report 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9f9f48/traumatic_brain) has announced the addition of the "Traumatic Brain Injury - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Traumatic Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adamas Pharmaceuticals, Inc. - ALSP, Inc. - Amarantus Bioscience Holdings, Inc. - Athersys, Inc. - BHR Pharma, LLC - Cognosci, Inc. - Concert Pharmaceuticals, Inc. - Euroscreen S.A. - Grupo Ferrer Internacional, S.A. - International Stem Cell Corporation - Io Therapeutics, Inc. - Ischemix - Karyopharm Therapeutics, Inc. - Kyorin Pharmaceutical Co., Ltd. - Levolta Pharmaceuticals, Inc. - Lixte Biotechnology Holdings, Inc. - Lpath, Inc. - MandalMed, Inc. - Mapreg S.A.S. - Mnemosyne Pharmaceuticals, Inc. - NeoStem, Inc. - Neuralstem, Inc. - Neuren Pharmaceuticals Limited - PharmatrophiX, Inc. - Phylogica Limited - Prevacus, Inc. - PsychoGenics, Inc. - QR Pharma, Inc. - RAPID Pharmaceuticals AG - RegeneRx Biopharmaceuticals, Inc. - SynZyme Technologies, LLC - Tetra Discovery Partners LLC - vasopharm GmbH - VG Life Sciences, Inc. For more information visit http://www.researchandmarkets.com/research/9f...atic_brain
NBS: 2.37 (-0.01), LPTN: 1.75 (-0.08), CNCE: 14.20 (+0.07), ATHX: 1.33 (+0.06), KPTI: 27.02 (+2.21), CUR: 1.71 (+0.01)
Researchers Report that Long-Term Administration of Thymosin B4 in a Diabetic Animal Model Prevents Progression of Peripheral Neuropathy and Restores Sciatic Nerve Function
PR Newswire - Fri May 08, 8:00AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that independent researchers have reported that diabetic mice treated long-term with Thymosin B4 (TB4) have significantly improved motor and sensory function in the sciatic nerve compared to the untreated animals and that TB4 protects the nerves and reverses neurological damage in diabetic neuropathy.
Penny Stocks Alerts for RegeneRx, Key Energy Services, Zynga, American Security Resources, Axxess Pharma, and Ecosciences
PR Newswire - Wed May 06, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: RegeneRx Biopharmaceuticals (OTCMKTS:RGRX), Key Energy Services (NYSE:KEG), Zynga (NASDAQ:ZNGA), American Security Resources (OTCMKTS:ARSC), Axxess Pharma (OTCMKTS:AXXE), and Ecosciences (OTCMKTS:ECEZ).
KEG: 2.55 (-0.05), ZNGA: 2.97 (-0.08)
Researchers Report that Thymosin B4 has a Major Role in Dermal Burn Wound Healing
PR Newswire - Mon May 04, 7:32AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"
today announced that an independent team of researchers from South Korea have reported that Thymosin B4 (TB4) plays an important role in accelerating the repair of second-degree dermal burn wounds, induced in an experimental mouse model, by promoting blood vessel formation and causing rapid vascular remodeling of damaged dermal tissue. The research found that the underlying mechanism of action is via actin cytoskeletal remodeling and the action of heat-shock proteins, which are induced when tissues or cells are exposed to stress. Heat shock proteins function to allow other proteins to assume their correct structures. The research also confirmed that remodeling of F-actin was regulated by TB4 by demonstrating its healing effects in the in vivo model. RegeneRx awarded US PTO's notice of allowance for TB4 for healing and reversing cardiac tissue
M2 - Fri Apr 24, 5:17AM CDT
RegeneRx Biopharmaceuticals (Other OTC:RGRX) reported on Thursday the receipt of a Notice of Allowance from the US Patent and Trademark Office (PTO) for its patent application claiming the administration of Thymosin beta 4 (TB4) to treat cardiac tissue.
RegeneRx Receives Notice of Allowance For U.S. Patent For Healing and Reversing Heart and Coronary Vessel Damage After A Heart Attack with TB4
PR Newswire - Thu Apr 23, 9:24AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"
today announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application claiming the administration of Thymosin beta 4 (TB4) to treat cardiac tissue to heal and reverse heart and coronary vessel damage due to a heart attack, as well as to enhance the transition of immature heart cells into mature cells, among others. RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S.
PR Newswire - Thu Apr 16, 8:53AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"
today announced its U.S. joint venture with G-treeBNT (ReGenTree LLC) has retained Ora, Inc. to conduct a phase 3 clinical trial for the orphan disorder, neurotrophic keratopathy (NK), and a 2b/3 dose-response, confirmatory trial for dry eye syndrome (DES) in the U.S. Both trials will be testing ReGenTree's preservative-free eye drops, RGN-259/GBT201, this year. Each of these eye disorders was being targeted by RegeneRx prior to entering into the joint venture. /C O R R E C T I O N -- RegeneRx Biopharmaceuticals, Inc./
PR Newswire - Wed Apr 01, 8:40AM CDT
In the news release, RegeneRx's RGN-259 Meets Key Efficacy Objectives in Phase 2 Clinical Trial in Patients with Severe Dry Eye Reported in Current Issue of Cornea, issued 01-Apr-2015 by RegeneRx Biopharmaceuticals, Inc. over PR Newswire, we are advised by the company that there were changes to the second paragraph of the release. The complete, corrected release follows:
RegeneRx's RGN-259 Meets Key Efficacy Objectives in Phase 2 Clinical Trial in Patients with Severe Dry Eye Reported in Current Issue of Cornea
PR Newswire - Wed Apr 01, 7:36AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"
today announced that a new medical paper has been published describing the positive effects of Thymosin beta 4 (TB4) in patients with severe dry eye. The results met key efficacy objectives of the study and the physicians stated that statistically significant differences in both signs and symptoms of severe dry eye were seen at various time points throughout the study. Of particular note at day 56, the RGN-259-treated group had 35.1% reduction of ocular discomfort compared with vehicle control (P=0.0141), and 59.1% reduction of total corneal fluorescein staining compared with vehicle control (P = 0.0108). Other improvements seen in the RGN-259-treated patients included tear film breakup time and increased tear volume production. RegeneRx Receives Israeli Patent Acceptance Notice for the Use of TB4 To Prevent Tissue Damage Associated with Heart Attack and Stroke Treatments
PR Newswire - Thu Mar 26, 9:26AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX)("the Company" or "RegeneRx"
today announced that it has received a patent acceptance notice from the Israeli patent office with claims for administering Thymosin beta 4 (TB4) to prevent or reduce tissue damage caused by an increase in blood flow, as is often the case when cardiac vessels are opened after a blockage causing a heart attack or in similar circumstances when treating stroke victims. RegeneRx Receives Initial Payment for RGN-259 U.S. License to ReGenTree Joint Venture
PR Newswire - Wed Mar 25, 7:55AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or the "Company"
has received an initial payment of $500,000 from ReGenTree, LLC, its U.S. joint venture with G-TreeBNT Co. Ltd., pursuant to a license of RGN-259 for ophthalmic indications to ReGenTree. RegeneRx expects to receive a second payment of $500,000 later this year upon enrollment of the first patient in a U.S. ophthalmic clinical trial sponsored by ReGenTree. ReGenTree is planning a Phase III trial for neurotrophic keratopathy (an orphan indication) and a Phase II trial for dry eye syndrome in the U.S., both to begin later this year. RegeneRx Joint Venture Partner Receives $7.28 million USD From Korean Government and Venture Fund for U.S. Development of RGN-259/GBT-201
PR Newswire - Mon Mar 09, 7:30AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"
has been notified that its joint venture partner and licensee, G-treeBNT Co. Ltd., will receive $7.28 million USD to expand international development of its product candidate, RGN-259 (designated GBT-201). Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases
PR Newswire - Tue Mar 03, 8:00AM CST
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"
In an editorial in the scientific journal, Expert Opinion on Biological Therapy, Dr. Michael Chopp and his colleague, Dr. Zhenggang Zhang, at the Henry Ford Hospital in Detroit, Michigan reported that Thymosin beta 4 (TB4) has the capacity to promote CNS and peripheral nervous system (PNS) remodeling 24 hours or more post-injury, leading to neurological recovery in each case. They pointed out that oligodendrogenesis and myelination are two of several common links in their studies by which TB4 promotes "self-recovery" and suggest that treatment strategies should be focused on pharmacologically enhancing the brain's own restorative abilities. Peripheral Neuropathy (Sensory Neuropathy) Therapeutics Pipeline Review 2015 - 10 Drug Profiles & 16 Drug Profiles
M2 - Tue Mar 03, 6:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/mh4n22/peripheral) has announced the addition of the "Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acorda Therapeutics, Inc. - aTyr Pharma, Inc. - GeNeuro SA - INSYS Therapeutics, Inc. - Mitsubishi Tanabe Pharma Corporation - Neuren Pharmaceuticals Limited - Pfizer Inc. - RegeneRx Biopharmaceuticals, Inc. - Takeda Pharmaceutical Company Limited - Teijin Pharma Limited Drug Profiles - cannabidiol - fingolimod hydrochloride - GL-2045 - immune globulin (human) - Monoclonal Antibody for CIDP - NNZ-2591 - NP-1998 - NRP-2945 - Peptide to Activate GLP1R for CNS, Metabolic Disorders and Head Trauma - Peptides for Neuropathic Pain and Peripheral Neuropathy - Peptides to Activate GLP-1 Receptor for CNS Disorders and Head Trauma - Proteins for Inflammation, Hematological, Metabolic, Oncology, Neurodegenerative and Cardiovascular Disorder - RGN-352 - Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis - Small Molecules to Inhibit Cysteine Protease and Caspases for Oncology, Immunology, Infectious and CNS Disorders - Synthetic Peptides for Peripheral Neuropathy For more information visit http://www.researchandmarkets.com/research/mh4n22/peripheral
INSY: 59.68 (+0.68), PFE: 33.98 (-0.01), ACOR: 30.71 (+0.67)
RegeneRx Updates Website
PR Newswire - Thu Feb 19, 7:30AM CST
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"
updated its website to reflect recent commercial transactions and information related to development of its clinical products. The site can be accessed at www.regenerx.com. RegeneRx Releases Letter to Shareholders
PR Newswire - Tue Feb 17, 7:30AM CST
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"
today released the following letter to shareholders: Sensory Neuropathy Therapeutics Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com
PRWeb - Tue Feb 10, 7:31AM CST
The report "Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy). Peripheral Neuropathy (Sensory Neuropathy) is a damage to one or more of peripheral nerves that includes motor, sensory and autonomic fibers. The cause of peripheral neuropathy is often unidentified. The most widespread causes of peripheral neuropathy are diabetes, shingles, kidney failure, various drugs and vitamin shortage. When the peripheral sensory nerves are damaged, they fail to send sensory messages (pain, heat, touch, cold etc). Neuropathy occurs in 60% to 70% of people with diabetes. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available @ http://www.rnrmarketresearch.com/peripheral-n...eport.html .
PFE: 33.98 (-0.01)
RegeneRx & G-treeBNT partnership to develop RGN-259 in the US for ophthalmic indications
M2 - Fri Jan 30, 2:14AM CST
Biopharmaceutical company RegeneRx Biopharmaceuticals (Other OTC:RGRX) reported on Wednesday the launch of an agreement to develop RGN-259 for dry eye syndrome and neurotrophic keratitis (an orphan indication) in the US in partnership with Korean-based pharma company G-treeBNT Co.
RegeneRx and G-treeBNT Create Joint Venture to Develop RGN-259 in the U.S.
PR Newswire - Wed Jan 28, 11:11AM CST
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"
today announced that it has entered into agreements with G-treeBNT Co. Ltd., to develop RGN-259 for dry eye syndrome and neurotrophic keratitis (an orphan indication) in the United States. Under the terms of a joint venture (JV) agreement between the parties, G-treeBNT will be responsible for conducting and funding all clinical trials and product development through approval of a new drug application (NDA). Pursuant to the terms of a license agreement between RegeneRx and the joint venture entity, RegeneRx granted the JV an exclusive, royalty-bearing license to market and sell RGN-259 in the U.S. RegeneRx also contributed all of its non-clinical and clinical data generated to date. G-treeBNT will hold a majority equity stake in the JV that will increase as it successfully reaches development milestones. RegeneRx has the right to participate in all key development and commercialization decisions under the agreements, including the right to approve key commercial relationships and transactions, such as product licensing, mergers or acquisitions. RegeneRx Partner Submits Phase IIB/III IND to Korean Health Authority for RGN-259 for the Treatment of Dry Eye Syndrome
PR Newswire - Mon Dec 29, 7:30AM CST
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"
announced that its strategic partner, G-treeBNT Co. Ltd., has filed an IND with the Korean Ministry of Food and Drug Safety (MFDS) for a Phase IIB/III clinical trial with RGN-259 (designated GBT-201 in Korea and the licensed Pan Asia territory) for the treatment of patients with dry eye syndrome. 
